Latest Articles

Publication Date
Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial - Nature

Maintenance olaparib after platinum-based chemotherapy for advanced/metastatic endometrial cancer: GINECO randomized phase IIb UTOLA trial Nature

Published: Aug. 26, 2025, 11:43 a.m.
Trend analysis for Yiren Digital Ltd. Depositary Receipt this week - July 2025 Analyst Calls & AI Based Buy and Sell Signals - Newser

Trend analysis for Yiren Digital Ltd. Depositary Receipt this week - July 2025 Analyst Calls & AI Based Buy and Sell Signals Newser

Published: Aug. 26, 2025, 5:25 a.m.
$10M for women’s health: Tackling menstruation, Lyme disease, and more - LymeDisease.org

$10M for women’s health: Tackling menstruation, Lyme disease, and more LymeDisease.org

Published: Aug. 24, 2025, 7:10 p.m.
Belfast girl, 4, diagnosed with rare disease which could lead to 'childhood dementia' - Belfast Live

Belfast girl, 4, diagnosed with rare disease which could lead to 'childhood dementia' Belfast Live

Published: Aug. 24, 2025, 6:51 p.m.
computing power impact of jobs blockchain technology - Weekly Gains Summary & Free Technical Pattern Based Buy Signals - Newser

computing power impact of jobs blockchain technology - Weekly Gains Summary & Free Technical Pattern Based Buy Signals Newser

Published: Aug. 24, 2025, 1:57 a.m.
Using flow based indicators on Integrated Media Technology Limited - July 2025 Chart Watch & Advanced Swing Trade Entry Alerts - Newser

Using flow based indicators on Integrated Media Technology Limited - July 2025 Chart Watch & Advanced Swing Trade Entry Alerts Newser

Published: Aug. 23, 2025, 5:24 a.m.
Real time breakdown of Brainstorm Cell Therapeutics Inc. stock performance - 2025 Analyst Calls & Momentum Based Trading Signals - Newser

Real time breakdown of Brainstorm Cell Therapeutics Inc. stock performance - 2025 Analyst Calls & Momentum Based Trading Signals Newser

Published: Aug. 22, 2025, 6:09 p.m.
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer - TipRanks

BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer TipRanks

Published: Aug. 22, 2025, 4:17 p.m.
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - TipRanks

BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer TipRanks

Published: Aug. 20, 2025, 4:07 p.m.
AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? - TipRanks

AstraZeneca’s Phase III Study on Endometrial Cancer: A Potential Game Changer? TipRanks

Published: Aug. 20, 2025, 4:07 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!